$957 Million is the total value of EcoR1 Capital, LLC's 51 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 79.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PRTA | PROTHENA CORP PLC | $100,865,000 | -32.4% | 9,426,640 | 0.0% | 10.54% | -21.7% | |
| XNCR | XENCOR INC | $74,747,000 | -13.1% | 2,501,557 | 0.0% | 7.81% | +0.7% | |
| ARVN | Buy | ARVINAS INC | $61,580,000 | +11.9% | 1,528,031 | +14.1% | 6.43% | +29.7% |
| DRNA | Sell | DICERNA PHARMACEUTICALS INC | $61,472,000 | -23.1% | 3,346,301 | -7.8% | 6.42% | -10.8% |
| FATE | Buy | FATE THERAPEUTICS INC | $52,013,000 | +488.8% | 2,341,875 | +418.9% | 5.43% | +582.7% |
| IRWD | Buy | IRONWOOD PHARMACEUTICALS INC | $44,328,000 | -23.8% | 4,393,236 | +0.5% | 4.63% | -11.7% |
| ANAB | Buy | ANAPTYSBIO INC | $42,899,000 | +34.3% | 3,036,014 | +54.4% | 4.48% | +55.6% |
| NLTX | Sell | NEOLEUKIN THERAPEUTICS INC | $42,029,000 | -12.9% | 3,693,203 | -5.7% | 4.39% | +1.0% |
| MORF | Buy | MORPHIC HLDG INC | $41,444,000 | +12.1% | 2,823,141 | +31.0% | 4.33% | +29.9% |
| ASMB | Buy | ASSEMBLY BIOSCIENCES INC | $38,420,000 | -21.4% | 2,590,680 | +8.5% | 4.01% | -8.9% |
| KURA | Sell | KURA ONCOLOGY INC | $34,941,000 | -40.1% | 3,511,690 | -17.2% | 3.65% | -30.6% |
| FGEN | Sell | FIBROGEN INC | $30,654,000 | -52.1% | 882,138 | -40.9% | 3.20% | -44.5% |
| IPHA | Sell | INNATE PHARMA S Asponsored ads | $29,831,000 | +1.9% | 4,465,668 | -1.8% | 3.12% | +18.1% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $27,508,000 | +228.4% | 357,849 | +450.5% | 2.87% | +280.7% |
| PRVL | PREVAIL THERAPEUTICS INC | $27,407,000 | -23.0% | 2,248,306 | 0.0% | 2.86% | -10.8% | |
| PBYI | New | PUMA BIOTECHNOLOGY INC | $21,405,000 | – | 2,536,156 | +100.0% | 2.24% | – |
| MRUS | Sell | MERUS N V | $20,763,000 | -14.2% | 1,715,962 | -0.1% | 2.17% | -0.5% |
| BCEL | Sell | ATRECA INC | $18,307,000 | -20.1% | 1,106,180 | -25.3% | 1.91% | -7.5% |
| RARE | Buy | ULTRAGENYX PHARMACEUTICAL IN | $16,493,000 | +47.6% | 371,208 | +41.9% | 1.72% | +71.1% |
| SGMO | New | SANGAMO THERAPEUTICS INC | $14,702,000 | – | 2,308,079 | +100.0% | 1.54% | – |
| GMAB | New | GENMAB A/Ssponsored ads | $13,858,000 | – | 653,981 | +100.0% | 1.45% | – |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $13,684,000 | -36.0% | 323,889 | -35.2% | 1.43% | -25.8% |
| DNLI | New | DENALI THERAPEUTICS INC | $12,224,000 | – | 698,101 | +100.0% | 1.28% | – |
| FOLD | New | AMICUS THERAPEUTICS INC | $11,546,000 | – | 1,249,611 | +100.0% | 1.21% | – |
| SELB | SELECTA BIOSCIENCES INC | $11,080,000 | +1.3% | 4,597,701 | 0.0% | 1.16% | +17.4% | |
| IONS | New | IONIS PHARMACEUTICALS INC | $9,863,000 | – | 208,609 | +100.0% | 1.03% | – |
| VIR | New | VIR BIOTECHNOLOGY INC | $9,267,000 | – | 270,418 | +100.0% | 0.97% | – |
| ZIOP | New | ZIOPHARM ONCOLOGY INC | $9,188,000 | – | 3,750,000 | +100.0% | 0.96% | – |
| VSTM | New | VERASTEM INC | $8,595,000 | – | 3,255,813 | +100.0% | 0.90% | – |
| BMYRT | New | BRISTOL-MYERS SQUIBB COright 99/99/9999 | $8,544,000 | – | 2,248,300 | +100.0% | 0.89% | – |
| CYCN | Buy | CYCLERION THERAPEUTICS INC | $7,267,000 | +47.5% | 2,742,276 | +51.4% | 0.76% | +70.9% |
| CHMA | Sell | CHIASMA INC | $5,521,000 | -63.4% | 1,512,627 | -50.3% | 0.58% | -57.6% |
| CRNX | New | CRINETICS PHARMACEUTICALS IN | $5,145,000 | – | 350,000 | +100.0% | 0.54% | – |
| XCUR | Sell | EXICURE INC | $4,205,000 | -58.5% | 2,841,301 | -19.8% | 0.44% | -52.0% |
| RCUS | Sell | ARCUS BIOSCIENCES INC | $4,054,000 | -45.0% | 292,100 | -60.0% | 0.42% | -36.1% |
| SVRA | SAVARA INC | $3,037,000 | -52.7% | 1,432,664 | 0.0% | 0.32% | -45.2% | |
| LSACU | New | LIFESCI ACQUISITION CORPunit 03/31/2025 | $3,000,000 | – | 300,000 | +100.0% | 0.31% | – |
| SURF | Sell | SURFACE ONCOLOGY INC | $2,383,000 | -2.6% | 1,274,463 | -2.1% | 0.25% | +12.7% |
| ACRS | ACLARIS THERAPEUTICS INC | $2,171,000 | -45.0% | 2,087,312 | 0.0% | 0.23% | -36.2% | |
| CRVS | CORVUS PHARMACEUTICALS INC | $1,556,000 | -61.2% | 737,612 | 0.0% | 0.16% | -55.0% | |
| ZYME | New | ZYMEWORKS INC | $1,469,000 | – | 41,407 | +100.0% | 0.15% | – |
| CRSP | New | CRISPR THERAPEUTICS AGnamen akt | $1,294,000 | – | 30,510 | +100.0% | 0.14% | – |
| MGTX | New | MEIRAGTX HOLDINGS PLC | $1,274,000 | – | 94,819 | +100.0% | 0.13% | – |
| New | TRILLIUM THERAPEUTICS INC | $1,180,000 | – | 291,997 | +100.0% | 0.12% | – | |
| XOMA | New | XOMA CORP DEL | $1,034,000 | – | 50,809 | +100.0% | 0.11% | – |
| RGLS | New | REGULUS THERAPEUTICS INC | $870,000 | – | 1,886,812 | +100.0% | 0.09% | – |
| BPMC | New | BLUEPRINT MEDICINES CORP | $816,000 | – | 13,946 | +100.0% | 0.08% | – |
| PIRS | Sell | PIERIS PHARMACEUTICALS INC | $602,000 | -93.4% | 264,166 | -89.6% | 0.06% | -92.4% |
| FPRX | New | FIVE PRIME THERAPEUTICS INC | $581,000 | – | 256,075 | +100.0% | 0.06% | – |
| EXEL | New | EXELIXIS INC | $108,000 | – | 6,269 | +100.0% | 0.01% | – |
| CTMX | Sell | CYTOMX THERAPEUTICS INC | $8,000 | -99.8% | 1,101 | -99.7% | 0.00% | -99.7% |
| UROV | Exit | UROVANT SCIENCES LTD | $0 | – | -26,468 | -100.0% | -0.04% | – |
| VCEL | Exit | VERICEL CORP | $0 | – | -131,001 | -100.0% | -0.20% | – |
| TCRR | Exit | TCR2 THERAPEUTICS INC | $0 | – | -239,500 | -100.0% | -0.31% | – |
| IGMS | Exit | IGM BIOSCIENCES INC | $0 | – | -100,000 | -100.0% | -0.34% | – |
| XFOR | Exit | X4 PHARMACEUTICALS INC | $0 | – | -415,400 | -100.0% | -0.40% | – |
| RUBY | Exit | RUBIUS THERAPEUTICS INC | $0 | – | -525,877 | -100.0% | -0.45% | – |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INC | $0 | – | -213,647 | -100.0% | -0.53% | – |
| EIGR | Exit | EIGER BIOPHARMACEUTICALS INC | $0 | – | -449,338 | -100.0% | -0.60% | – |
| EOLS | Exit | EVOLUS INC | $0 | – | -600,000 | -100.0% | -0.66% | – |
| SAGE | Exit | SAGE THERAPEUTICS INC | $0 | – | -173,364 | -100.0% | -1.13% | – |
| HARP | Exit | HARPOON THERAPEUTICS INC | $0 | – | -908,547 | -100.0% | -1.21% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INCcall | $0 | – | -312,500 | -100.0% | -2.38% | – |
| FGEN | Exit | FIBROGEN INCcall | $0 | – | -676,500 | -100.0% | -2.62% | – |
| ARGX | Exit | ARGENX SEsponsored adr | $0 | – | -202,117 | -100.0% | -2.92% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KURA ONCOLOGY ORD | 32 | Q3 2023 | 10.5% |
| XENCOR ORD | 25 | Q3 2023 | 12.6% |
| ASSEMBLY BIOSCIENCES ORD | 23 | Q3 2020 | 19.0% |
| FIBROGEN ORD | 22 | Q1 2020 | 12.4% |
| PROTHENA ORD | 20 | Q3 2023 | 28.0% |
| IRONWOOD PHARMA CL A ORD | 20 | Q1 2020 | 13.9% |
| GALAPAGOS NV SPON ADR | 19 | Q3 2023 | 12.0% |
| MORPHIC HOLDING ORD | 18 | Q3 2023 | 8.5% |
| ARCUS BIOSCIENCES ORD | 17 | Q1 2022 | 7.1% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 8.3% |
View EcoR1 Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Mersana Therapeutics, Inc. | July 27, 2023 | 19,364,688 | 16.9% |
| TScan Therapeutics, Inc. | June 05, 2023 | 5,000,000 | 11.7% |
| 2seventy bio, Inc. | February 14, 2023 | 1,143,494 | 3.0% |
| Avidity Biosciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Surface Oncology, Inc. | February 13, 2023 | 3,924,713 | 6.5% |
| Akouos, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Alector, Inc. | February 10, 2023 | 4,056,548 | 4.9% |
| Arcus Biosciences, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Gritstone bio, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Ovid Therapeutics Inc. | February 10, 2023 | 6,117,400 | 8.7% |
View EcoR1 Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-08 |
| 3 | 2024-03-26 |
| SC 13G/A | 2024-03-26 |
| SC 13G | 2024-03-11 |
| SC 13D | 2024-02-22 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View EcoR1 Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.